Keytruda in early-stage triple-negative breast cancer led to immune-related adverse effects, including severe GI issues and ...

KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless ...

Ivonescimab reduced the risk of disease progression or death by 49% compared with pembrolizumab in patients with PD-L1–positive advanced non–small cell lung cancer. Ivonescimab reduced the risk of ...

Dr. Shannon Westin (Host), Dr. Brian Slomovitz (Guest) Dr. Shannon Westin and her guest, Dr. Brian Slomovitz discuss the article “Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without ...

We have also today recommended pembrolizumab with chemotherapy before surgery (neoadjuvant) then pembrolizumab alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer.

Checkpoint inhibitors are a type of immunotherapy. These drugs block different proteins called checkpoint proteins that stop the immune system from attacking the cancer cells. They are a treatment for ...